
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
0:00
12:05
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial."
Fler avsnitt från "Journal of Clinical Oncology (JCO) Podcast"



Missa inte ett avsnitt av “Journal of Clinical Oncology (JCO) Podcast” och prenumerera på det i GetPodcast-appen.








